Cabozantinib Dose Skipping as an Alternative to Dose Reductions

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

September 1, 2027

Study Completion Date

September 1, 2028

Conditions
Renal Cell Carcinoma (RCC)
Interventions
DRUG

Cabozantinib

For patients using 40mg the experimental regimen consists of 60mg once daily for 2 days followed by 1 skipping day (60-60-0 mg). For patients using 20mg the experimental regimen consists of 60mg once daily for 1 day followed by 2 skipping days (60-0-0 mg).

All Listed Sponsors
lead

dr. Tom van der Hulle

OTHER